ETFDH mutation involves excessive apoptosis and neurite outgrowth defect via Bcl2 pathway.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
25 Oct 2024
Historique:
received: 23 03 2024
accepted: 03 10 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 25 10 2024
Statut: epublish

Résumé

The most common mutation in southern Chinese individuals with late-onset multiple acyl-coenzyme A dehydrogenase deficiency (MADD; a fatty acid metabolism disorder) is c.250G > A (p.Ala84Thr) in the electron transfer flavoprotein dehydrogenase gene (ETFDH). Various phenotypes, including episodic weakness or rhabdomyolysis, exercise intolerance, and peripheral neuropathy, have been reported in both muscular and neuronal contexts. Our cellular models of MADD exhibit neurite growth defects and excessive apoptosis. Given that axonal degeneration and neuronal apoptosis may be regulated by B-cell lymphoma (BCL)-2 family proteins and mitochondrial outer membrane permeabilization through the activation of proapoptotic molecules, we measured the expression levels of proapoptotic BCL-2 family proteins (e.g., BCL-2-associated X protein and p53-upregulated modulator of apoptosis), cytochrome c, caspase-3, and caspase-9 in NSC-34 cells carrying the most common ETFDH mutation. The levels of these proteins were higher in the mutant cells than in the wide-type cells. Subsequent treatment of the mutant cells with coenzyme Q10 downregulated activated protein expression and mitigated neurite growth defects. These results suggest that the activation of the BCL-2/mitochondrial outer membrane permeabilization/apoptosis pathway promotes apoptosis in cellular models of MADD and that coenzyme Q10 can reverse this effect. Our findings aid the development of novel therapeutic strategies for reducing axonal degeneration and neuronal apoptosis in MADD.

Identifiants

pubmed: 39455656
doi: 10.1038/s41598-024-75286-4
pii: 10.1038/s41598-024-75286-4
doi:

Substances chimiques

Proto-Oncogene Proteins c-bcl-2 0
Electron-Transferring Flavoproteins 0
Iron-Sulfur Proteins 0
electron-transferring-flavoprotein dehydrogenase EC 1.5.5.1
Oxidoreductases Acting on CH-NH Group Donors EC 1.5.-
Ubiquinone 1339-63-5
coenzyme Q10 EJ27X76M46

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

25374

Subventions

Organisme : Kaohsiung Medical University Chung-Ho Memorial Hospital
ID : KMUH-106-6R46.
Organisme : Chi-Mei Medical Center and Kaohsiung Medical University, Taiwan
ID : 108CM-KMU-08
Organisme : Chi-Mei Medical Center and Kaohsiung Medical University, Taiwan
ID : 108CM-KMU-08

Informations de copyright

© 2024. The Author(s).

Références

Indo, Y., Glassberg, R., Yokota, I. & Tanaka, K. Molecular characterization of variant alpha-subunit of electron transfer flavoprotein in three patients with glutaric acidemia type II–and identification of glycine substitution for valine-157 in the sequence of the precursor, producing an unstable mature protein in a patient. Am. J. Hum. Genet. 49, 575–580 (1991).
pubmed: 1882842 pmcid: 1683153
Freneaux, E., Sheffield, V. C., Molin, L., Shires, A. & Rhead, W. J. Glutaric acidemia type II. Heterogeneity in beta-oxidation flux, polypeptide synthesis, and complementary DNA mutations in the alpha subunit of electron transfer flavoprotein in eight patients. J. Clin. Invest. 90, 1679–1686 (1992).
pubmed: 1430199 pmcid: 443224 doi: 10.1172/JCI116040
Beard, S. E., Goodman, S. I., Bemelen, K. & Freman, F. E. Characterization of a mutation that abolishes quinone reduction by electron transfer flavoprotein-ubiquinone oxidoreductase. Hum. Mol. Genet. 4, 157–161 (1995).
pubmed: 7757062 doi: 10.1093/hmg/4.2.157
Goodman, S. I., Binard, R. J., Woontner, M. R. & Freman, F. E. Glutaric acidemia type II: gene structure and mutations of the electron transfer flavoprotein:ubiquinone oxidoreductase (ETF:QO) gene. Mol. Genet. Metab. 77, 86–90 (2002).
pubmed: 12359134 doi: 10.1016/S1096-7192(02)00138-5
Ghisla, S. & Thorpe, C. Acyl-CoA dehydrogenases. A mechanistic overview. Eur. J. Biochem. 271, 494–508 (2004).
pubmed: 14728676 doi: 10.1046/j.1432-1033.2003.03946.x
Van Hove, J. L. K. et al. D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD). Lancet. 361, 1433–1435 (2003).
pubmed: 12727399 doi: 10.1016/S0140-6736(03)13105-4
Ishii, K. et al. Central nervous system and muscle involvement in an adolescent patient with riboflavin responsive multiple acyl-CoA dehydrogenase deficiency. Brain Dev. 32, 669–672 (2010).
pubmed: 19783111 doi: 10.1016/j.braindev.2009.08.008
Wang, Z. et al. Severe sensory neuropathy in patients with adult-onset multiple acyl-CoA dehydrogenase deficiency. Neuromuscul. Disord. 26, 170–175 (2016).
pubmed: 26821934 doi: 10.1016/j.nmd.2015.12.002
Hong, D., Yu, Y., Wang, Y., Xu, Y. & Zhang, J. Acute-onset multiple acyl-CoA dehydrogenase deficiency mimicking Guillain-Barré syndrome: two cases report. BMC Neurol. 18, 219 (2018).
pubmed: 30587156 pmcid: 6306005 doi: 10.1186/s12883-018-1221-2
Huang, K., Duan, H. Q., Li, Q. X., Luo, Y. B. & Yang, H. Investigation of adult-onset multiple acyl-CoA dehydrogenase deficiency associated with peripheral neuropathy. Neuropathology. 40, 531–539 (2020).
pubmed: 32608139 doi: 10.1111/neup.12667
Lupica, A. et al. Diagnostic challenges in late onset multiple acyl-CoA dehydrogenase deficiency: clinical, morphological, and genetic aspects. Front. Neurol. 13, 815523 (2022).
pubmed: 35309592 pmcid: 8929684 doi: 10.3389/fneur.2022.815523
Gregersen, N., Christensen, M. F., Christensen, E. & Kølvraa, S. Riboflavin responsive multiple acyl-CoA dehydrogenation deficiency. Assessment of 3 years of riboflavin treatment. Acta Paediatr. Scand. 75, 676–681 (1986).
pubmed: 3751563 doi: 10.1111/j.1651-2227.1986.tb10272.x
Zhang, J., Frerman, F. E. & Kim, J. J. Structure of electron transfer flavoprotein-ubiquinone oxidoreductase and electron transfer to the mitochondrial ubiquinone pool. Proc. Natl. Acad. Sci. U. S. A. 103,16212–16217 (2006).
Olsen, R. K. et al. ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain. 130, 2045–2054 (2007).
pubmed: 17584774 doi: 10.1093/brain/awm135
Lucas, T. G. et al. Cofactors and metabolites as potential stabilizers of mitochondrial acyl-CoA dehydrogenases. Biochim. Biophys. Acta. 1812, 1658–1663 (2011).
pubmed: 21968293 doi: 10.1016/j.bbadis.2011.09.009
Cornelius, N. et al. Molecular mechanisms of riboflavin responsiveness in patients with ETF-QO variations and multiple acyl-CoA dehydrogenation deficiency. Hum. Mol. Genet. 21, 3435–3448 (2012).
pubmed: 22611163 doi: 10.1093/hmg/dds175
Angelini, C. Spectrum of metabolic myopathies. Biochim. Biophys. Acta. 1852, 615–621 (2015).
pubmed: 24997454 doi: 10.1016/j.bbadis.2014.06.031
Xu, J. et al. ETFDH mutations and flavin adenine dinucleotide homeostasis disturbance are essential for developing riboflavin-responsive multiple acyl-coenzyme A dehydrogenation deficiency. Ann. Neurol. 84, 659–673 (2018).
pubmed: 30232818 doi: 10.1002/ana.25338
Song, Y. et al. Mechanisms underlying metabolic and neural defects in zebrafish and human multiple acyl-CoA dehydrogenase deficiency (MADD). PLoS One. 4, e8329. https://doi.org/10.1371/journal.pone.0008329 (2009).
doi: 10.1371/journal.pone.0008329 pubmed: 20020044 pmcid: 2791221
Gould, T. W. et al. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J. Neurosci. 26, 8774–8786 (2006).
pubmed: 16928866 pmcid: 6674380 doi: 10.1523/JNEUROSCI.2315-06.2006
Kumari, S., Dhapola, R. & Reddy, D. H. K. Apoptosis in Alzheimer’s disease: insight into the signaling pathways and therapeutic avenues. Apoptosis. 28, 943–957 (2023).
pubmed: 37186274 doi: 10.1007/s10495-023-01848-y
Risner, M. L., Pasini, S., McGrady, N. R. & Calkins, D. J. Bax contributes to retinal ganglion cell dendritic degeneration during Glaucoma. Mol. Neurobiol. 59, 366–1380 (2022).
doi: 10.1007/s12035-021-02675-5
Tian, F. et al. Glutaric acid-mediated apoptosis in primary striatal neurons. Biomed. Res. Int. 484731 (2014). (2014).
Liang, W. C. et al. ETFDH mutations, CoQ10 levels, and respiratory chain activities in patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Neuromuscul. Disord. 19, 212–216 (2009).
pubmed: 19249206 pmcid: 10409523 doi: 10.1016/j.nmd.2009.01.008
Wang, Z. Q., Chen, X. J., Murong, S. X., Wang, N. & Wu, Z. Y. Molecular analysis of 51 unrelated pedigrees with late-onset multiple acyl-CoA dehydrogenation deficiency (MADD) in southern China confirmed the most common ETFDH mutation and high carrier frequency of c.250G > A. J. Mol. Med. (Berl). 89, 569–576 (2011).
pubmed: 21347544 doi: 10.1007/s00109-011-0725-7
Liang, W. C. et al. Neurite growth could be impaired by ETFDH mutation but restored by mitochondrial cofactors. Muscle Nerve. 56, 479–485 (2017).
pubmed: 27935074 doi: 10.1002/mus.25501
Nakamura, A. et al. Cellular level of coenzyme Q increases with neuronal differentiation, playing an important role in neural elongations. J. Clin. Biochem. Nutr. 71, 89–96 (2022).
pubmed: 36213795 pmcid: 9519416 doi: 10.3164/jcbn.21-107
Kale, J., Osterlund, E. J. & Andrews, D. W. BCL-2 family proteins:changing partners in the dance towards death. Cell. Death Differ. 25, 65–80 (2018).
pubmed: 29149100 doi: 10.1038/cdd.2017.186
Misgeld, T. & Schwarz, T. L. Mitostasis in neurons: maintaining mitochondria in an extended cellular architecture. Neuron. 96, 651–666 (2017).
pubmed: 29096078 pmcid: 5687842 doi: 10.1016/j.neuron.2017.09.055
Li, X. et al. Coenzyme Q10 suppresses oxidative stress and apoptosis via activating the Nrf-2/NQO-1 and NF-κB signaling pathway after spinal cord injury in rats. Am. J. Transl Res. 11, 6544–6552 (2019).
pubmed: 31737205 pmcid: 6834524
Papucci, L. et al. Coenzyme Q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J. Biol. Chem. 278, 28220–28228 (2003).
pubmed: 12736273 doi: 10.1074/jbc.M302297200
Chokchaiwong, S. et al. Coenzyme Q10 serves to couple mitochondrial oxidative phosphorylation and fatty acid β-oxidation, and attenuates NLRP3 inflammasome activation. Free Radic Res. 52, 1445–1455 (2018).
pubmed: 30003820 doi: 10.1080/10715762.2018.1500695
Mosegaard, S. et al. Riboflavin deficiency-implications for general human health and inborn errors of metabolism. Int. J. Mol. Sci. 21, 3847 (2020).
pubmed: 32481712 pmcid: 7312377 doi: 10.3390/ijms21113847
Zhang, B. et al. Riboflavin (vitamin B2) deficiency induces apoptosis mediated by endoplasmic reticulum stress and the CHOP pathway in HepG2 cells. Nutrients. 14, 3356 (2022).
pubmed: 36014863 pmcid: 9414855 doi: 10.3390/nu14163356
Olfat, N., Ashoori, M. & Saedisomeolia, A. Riboflavin is an antioxidant: a review update. Br. J. Nutr. 128, 1887–1895 (2022).
pubmed: 35115064 doi: 10.1017/S0007114521005031
Hu, H. et al. Apoptosis as an underlying mechanism in lymphocytes induced by riboflavin and ultraviolet light. Transfus. Apher Sci. 59, 102899 (2020).
pubmed: 32778523 doi: 10.1016/j.transci.2020.102899
Herrero Martin, J. C. et al. An ETFDH-derived metabolon supports OXPHOS efficiency in skeletal muscle by regulating coenzyme Q homeostasisi. Nat. Metabolism. 6, 209–225 (2024).
doi: 10.1038/s42255-023-00956-y
Singh, R., Letai, A. & Sarosiek, K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat. Rev. 20, 175–193 (2019).
doi: 10.1038/s41580-018-0089-8
Cashman, N. R. et al. Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev. Dyn. 194, 209–221 (1992).
pubmed: 1467557 doi: 10.1002/aja.1001940306
Pfeiffer-Guglielmi, B. & Jansen, R. P. The motor neuron-like cell line NSC-34 and its parent cell line N18TG2 have glycogen that is degraded under cellular stress. Neurochem Res. 46, 1567–1576 (2021).
pubmed: 33786720 pmcid: 8084819 doi: 10.1007/s11064-021-03297-y
Matusica, D., Fenech, M. P., Rogers, M. L. & Rush, R. A. Characterization and use of the NSC-34 cell line for study of neurotrophin receptor trafficking. J. Neurosci. Res. 86, 553–565 (2008).
pubmed: 17896795 doi: 10.1002/jnr.21507
Lee, Y. Y. et al. Bcl-2 overexpression induces neurite outgrowth via the Bmp4/Tbx3/NeuroD1 cascade in H19-7 cells. Cell. Mol. Neurobiol. 40, 153–166 (2020).
pubmed: 31493044 doi: 10.1007/s10571-019-00732-1
Pemberton, J. M., Pogmore, J. P. & Andrews, D. W. Neuronal cell life, death, and axonal degeneration as regulated by the BCL-2 family proteins. Cell. Death Differ. 28, 108–122 (2021).
pubmed: 33162554 doi: 10.1038/s41418-020-00654-2
Kalkavan, H. & Green, D. R. MOMP, cell suicide as a BCL-2 family business. Cell. Death Differ. 25, 46–55 (2018).
pubmed: 29053143 doi: 10.1038/cdd.2017.179

Auteurs

Chuang-Yu Lin (CY)

Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan.
Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.

Wen-Chen Liang (WC)

Departments of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. wen.chen.liang@gmail.com.
Department of Pediatrics, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. wen.chen.liang@gmail.com.
Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. wen.chen.liang@gmail.com.
Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. wen.chen.liang@gmail.com.

Yi-Chen Yu (YC)

Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan.

Shin-Cheng Chang (SC)

Departments of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

Ming-Chi Lai (MC)

Department of Pediatrics, Chi-Mei Medical Center, Tainan, Taiwan. vickylai621@gmail.com.

Yuh-Jyh Jong (YJ)

Departments of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Department of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH